Article with Steven Ferris

Researchers are on the verge of testing a fundamental hypothesis about how Alzheimer's disease evolves.

Amyloid-β, the peptide responsible for the ugly plaques coating the brains of victims of the disease, has long been considered the main culprit in triggering neuron death and subsequent mental decline. After years of complex drug discovery efforts, industry is putting that hypothesis to the test with a series of late-stage clinical trials for small molecules and antibodies that block amyloid-β.

Read More: The Amyloid Question: Alzheimer's researchers will soon know whether blocking amyloid-β can slow down the debilitating disease.


Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.